The prevalence of heterozygous form is 1 in 500, with a higher ratio in certain populations. The homozygous form occurs in 1 in million. 2 Patient with homozygous condition usually presents at an earlier age with signs and symptoms of ischaemic heart disease and peripheral vascular disease. 3 Homozygotes with Familial Hypercholesterolaemia have a higher risk of aortic stenosis due to atherosclerotic involvement of the aortic root or the supravalvular region; but the incidence is relatively lower in heterozygotes. 4 Premature atherosclerosis in Familial Hypercholesterolaemia may affect the aortic root, but involvement of the aortic valve is a peculiar feature. 5 Premature aortic calcifications may also be present in adults presenting with Familial Hypercholestrolaemia. Individuals having valvular aortic stenosis may present with chest pain, syncopal attacks, dizziness or clinical features of heart failure.
Case Presentation
A 21-year-old male presented in the OutPatientDepartment with complaints of Exertional chest pain for 2 years and shortness of breath for 6 months.The pain was severe in intensity, radiated to the jaw and was relieved by rest. He also mentioned for eruptive skin lesion for last 7 years. There was no history of Rheumatic fever. There was no history of cough, palpitation, orthopnoea, syncope, sore throat or arthralgias. He did not smoke and denied any illicit drug use. He has one brother. His parents are alive and all his family members are healthy. No member of his maternal or paternal family had this sort of illness.
On physical examination, his pulse rate was 88/ minute, slow-rising, low-volume, regular in rhythm. His blood pressure was 100/70 mm of Hg. There was no pallor, jaundice, cyanosis, clubbing and JVP was not raised. On examination of his hand, xanthomatous lesions present over both eyelids, back of neck, back of elbows, knuckles, interdigital webs on both hands and had been there since the patient was 14 years of age ( Figure-1& 2 The patient is followed up regularly in the outpatient department and lipid profile is repeated every 3 months. Since his initial visit, his total serum cholesterol has decreased by 32% and his LDL level has decreased by 20%. Ezetemibe 10 mg/day was added. The goal is to bring down the cholesterol level to less than 200 mg/dl and LDL level to at least below 130 mg/dl which are near optimal values as recommended by ATP III guidelines. This would lead to an improvement in the cholesterol to HDL ratio which is the most important predictor of atherosclerosis. The patient is monitored for any adverse effects of the drug therapy and liver function tests are scheduled at regular intervals.
Discussion:
Familial Hypercholesterolaemia is a genetic disease with hereditary transmission, but it presents with a wide range of phenotypic expressions. The variability is the result of various types of underlying mutation in the LDL receptor gene all of which result in Familial Hypercholesterolaemia. Risk factors such as age, gender, smoking and hypertension also contribute to the clinical signs and symptoms seen in the patient at the time of the onset of the disease. 6 The typical manifestation seen in homozygous Familial Hypercholestrolaemia patients are coronary ostial stenosis and aortic root stenosis which occur due to cholesterol deposition in the aortic root at a young age. 7 Contrary to homozygous Familial Hypercholesterolaemia, in the heterozygous strain the usual age of presentation is highly variable and depends on the molecular defect in the LDL receptor gene.
Patients with coexisting cardiac disease risk factors may present at an earlier age with symptoms of cardiovascular disease. Most common cardiovascular presentation in homozygous Familial Hypercholestraemia is premature ischaemic heart disease, but relatively few cases present with earlier anginal symptoms due to atherosclerotic involvement of aortic root or supravalvular aortic stenosis. 8 There should be a high index of clinical suspicion in considering valvular heart disease when chest pain is reported with clinical and laboratory features suggesting homozygous Familial Hypercholestrolaemia in young adults. An earlier intervention of valvular aortic stenosis along with lipid-lowering therapy decreases morbidity and mortality. 9 Guyton JR et al reported in their study that a combination treatment with statin, ezetimibe and extendedrelease niacin may prove to be more beneficial than any of these drugs used alone. 10 Statin therapy also has the added advantage of improving endothelial dysfunction in Familial Hypercholesterolaemia patients. 
Conclusion:
Valvular aortic stenosis should be considered a possible diagnosis in young adults presenting with angina symptoms with clinical and laboratory features suggestive of homozygous Familial Hypercholestrolaemia. Early diagnosis and intervention may lead to decrease in morbidity and mortality.
